STL303 Safety and Efficacy for IgA Kidney Disease
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with primary IgA nephropathy (confirmed by a kidney biopsy)
- Your kidney function (eGFR) is at least 30 mL/min/1.73 m², and you have significant protein in your urine (at least 0.75 g/g)
- You have been on a maximum-dose blood pressure medication (ACE inhibitor or ARB) for at least 90 days before starting
- You are fully vaccinated against meningococcal and pneumococcal bacteria
- You do not have uncontrolled blood pressure (below 150/90) and no signs of immunodeficiency or recent infections
- You have not taken immunosuppressive drugs, oral budesonide, or complement inhibitors in the required washout periods
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (FXS6837) for people with IgA nephropathy (a kidney disease that causes protein in the urine and can lead to kidney damage). The goal is to see if it can reduce protein loss and protect kidney function.
This trial tests a new medicine called HS-10542 for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and helps reduce protein in the urine, which is a sign of kidney damage.
This early-phase study tests a new drug called YKST02 for people with primary IgA nephropathy, a kidney disease. It aims to see if the drug is safe and if it can help reduce kidney damage.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
Hear when a new IgAN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.